Analysis of ribonucleotide 5′-triphosphate analogs as potential inhibitors of Zika virus RNA-dependent RNA polymerase by using nonradioactive polymerase assays

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 3, 2017, Pages

  Lu, Gaofei ^a   Bluemling, Gregory R ^a   Collop, Paul ^a   Hager, Michael ^a   Kuiper, Damien ^a   Gurale, Bharat P ^a   Painter, George R ^a,b   De La Rosa, Abel ^a   Kolykhalov, Alexander A ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Nonradioactive assay; Polymerase assay; Polymerase inhibitor; RdRp; Zika virus; ZIKV

Indexed keywords

DOUBLE STRANDED DNA; NONSTRUCTURAL PROTEIN 5; RNA DIRECTED RNA POLYMERASE; SINGLE STRANDED DNA; ANTIVIRUS AGENT; DIVALENT CATION; MANGANESE; POLYPHOSPHATE; PRIMER DNA; RIBONUCLEOTIDE; TRIPHOSPHORIC ACID; VIRAL PROTEIN; VIRUS RNA;

ARTICLE; ENZYME ACTIVITY; ENZYME INHIBITION ASSAY; IC50; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RNA SYNTHESIS; ZIKA VIRUS; ANTAGONISTS AND INHIBITORS; BIOASSAY; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PROCEDURES; STAINING; SYNTHESIS; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BASE SEQUENCE; BIOLOGICAL ASSAY; CATIONS, DIVALENT; DNA PRIMERS; DNA, SINGLE-STRANDED; MANGANESE; POLYPHOSPHATES; PROTEIN DOMAINS; RIBONUCLEOTIDES; RNA REPLICASE; RNA, VIRAL; STAINING AND LABELING; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION; ZIKA VIRUS;

EID: 85014294475     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01967-16     Document Type: Article

References (41)

1. Dick G, Kitchen S, Haddow A. 1952. Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg 46:509-520. https://doi.org/10.1016/0035-9203(52)90042-4.
2. Besnard M, Lastère S, Teissier A, Cao-Lormeau V, Musso D. 2014. Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014. Euro Surveill 19:pii-20751. https://doi.org/10.2807/1560-7917.ES2014.19.13.20751.
3. Musso D, Roche C, Robin E, Nhan T, Teissier A, Cao-Lormeau V-M. 2015. Potential sexual transmission of Zika virus. Emerg Infect Dis 21:359. https://doi.org/10.3201/eid2102.141363.
4. Musso D, Gubler DJ. 2016. Zika virus. Clin Microbiol Rev 29:487-524. https://doi.org/10.1128/CMR.00072-15.
5. Mlakar J, Korva M, Tul N, Popović M, Poljšak-Prijatelj M, Mraz J, Kolenc M, Resman Rus K, Vesnaver Vipotnik T, Fabjan Vodušek V, Vizjak A, Pižem J, Petrovec M, Avšič, Županc T. 2016. Zika virus associated with microcephaly. N Engl J Med 374:951-958. https://doi.org/10.1056/NEJMoa1600651.
6. Yuki N, Hartung H-P. 2012. Guillain-Barré syndrome. N Engl J Med 366:2294-2304. https://doi.org/10.1056/NEJMra1114525.
7. Gulland A. 2016. Zika virus is a global public health emergency, declares WHO. BMJ 352:i657. https://doi.org/10.1136/bmj.i657.
8. Kuno G, Chang G-J. 2007. Full-length sequencing and genomic characterization of Bagaza, Kedougou, and Zika viruses. Arch Virol 152: 687-696. https://doi.org/10.1007/s00705-006-0903-z.
9. Lindenbach B, Murray C, Thiel H, Rice C. 2013. Flaviviridae, p 712-746. In Knipe DM, Howley PM, Cohen JI, Griffin DE, Lamb RA, Martin MA, Racaniello VR, Roizman B (ed), Fields virology, 6th ed, vol 1. Lippincott Williams & Wilkins, Philadelphia, PA.
10. Coloma J, Jain R, Rajashankar KR, García-Sastre A, Aggarwal AK. 2016. Structures of NS5 methyltransferase from Zika virus. Cell Rep 16: 3097-3102. https://doi.org/10.1016/j.celrep.2016.08.091.
11. Bollati M, Alvarez K, Assenberg R, Baronti C, Canard B, Cook S, Coutard B, Decroly E, de Lamballerie X, Gould EA. 2010. Structure and functionality in flavivirus NS-proteins: perspectives for drug design. Antiviral Res 87:125-148. https://doi.org/10.1016/j.antiviral.2009.11.009.
12. Zhou Y, Ray D, Zhao Y, Dong H, Ren S, Li Z, Guo Y, Bernard KA, Shi P-Y, Li H. 2007. Structure and function of flavivirus NS5 methyltransferase. J Virol 81:3891-3903. https://doi.org/10.1128/JVI.02704-06.
13. Gentile I, Borgia F, Buonomo RA, Castaldo G, Borgia G. 2013. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem 20: 3733-3742. https://doi.org/10.2174/09298673113209990178.
14. Powdrill MH, Bernatchez JA, Götte M. 2010. Inhibitors of the hepatitis C virus RNA-dependent RNA polymerase NS5B. Viruses 2:2169-2195. https://doi.org/10.3390/v2102169.
15. Malet H, Massé N, Selisko B, Romette J-L, Alvarez K, Guillemot JC, Tolou H, Yap TL, Vasudevan SG, Lescar J. 2008. The flavivirus polymerase as a target for drug discovery. Antiviral Res 80:23-35. https://doi.org/10.1016/j.antiviral.2008.06.007.
16. Chen Y-L, Yin Z, Duraiswamy J, Schul W, Lim CC, Liu B, Xu HY, Qing M, Yip A, Wang G, Chan WL, Tan HP, Lo M, Liung S, Kondreddi RR, Rao R, Gu H, He H, Keller TH, Shi PY. 2010. Inhibition of dengue virus RNA synthesis by an adenosine nucleoside. Antimicrob Agents Chemother 54: 2932-2939. https://doi.org/10.1128/AAC.00140-10.
17. Sofia MJ, Chang W, Furman PA, Mosley RT, Ross BS. 2012. Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase. J Med Chem 55:2481-2531. https://doi.org/10.1021/jm201384j.
18. Latour DR, Jekle A, Javanbakht H, Henningsen R, Gee P, Lee I, Tran P, Ren S, Kutach AK, Harris SF, Wang SM, Lok SJ, Shaw D, Li J, Heilek G, Klumpp K, Swinney DC, Deval J. 2010. Biochemical characterization of the inhibition of the dengue virus RNA polymerase by beta-D-2′-ethynyl-7-deaza-adenosine triphosphate. Antiviral Res 87:213-222. https://doi.org/10.1016/j.antiviral.2010.05.003.
19. Chen Y-L, Yokokawa F, Shi P-Y. 2015. The search for nucleoside/nucleotide analog inhibitors of dengue virus. Antiviral Res 122:12-19. https://doi.org/10.1016/j.antiviral.2015.07.010.
20. Degasperi E, Aghemo A. 2014. Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives. Hepat Med 6:25-33. https://doi.org/10.2147/HMER.S44375.
21. Cholongitas E, Papatheodoridis GV. 2014. Sofosbuvir: a novel oral agent for chronic hepatitis C. Ann Gastroenterol 27:331-337.
22. Waheed Y, Bhatti A, Ashraf M. 2013. RNA dependent RNA polymerase of HCV: a potential target for the development of antiviral drugs. Infect Genet Evol 14:247-257. https://doi.org/10.1016/j.meegid.2012.12.004.
23. Traut TW. 1994. Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 140:1-22. https://doi.org/10.1007/BF00928361.
24. Olsen DB, Eldrup AB, Bartholomew L, Bhat B, Bosserman MR, Ceccacci A, Colwell LF, Fay JF, Flores OA, Getty KL, Grobler JA, LaFemina RL, Markel EJ, Migliaccio G, Prhavc M, Stahlhut MW, Tomassini JE, MacCoss M, Hazuda DJ, Carroll SS. 2004. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob Agents Chemother 48:3944-3953. https://doi.org/10.1128/AAC.48.10.3944-3953.2004.
25. Nyrén P, Lundin A. 1985. Enzymatic method for continuous monitoring of inorganic pyrophosphate synthesis. Anal Biochem 151:504-509. https://doi.org/10.1016/0003-2697(85)90211-8.
26. Nyrén P. 1987. Enzymatic method for continuous monitoring of DNA polymerase activity. Anal Biochem 167:235-238. https://doi.org/10.1016/0003-2697(87)90158-8.
27. Ronaghi M, Karamohamed S, Pettersson B, Uhlén M, Nyrén P. 1996. Real-time DNA sequencing using detection of pyrophosphate release. Anal Biochem 242:84-89. https://doi.org/10.1006/abio.1996.0432.
28. Lahser FC, Malcolm BA. 2004. A continuous nonradioactive assay for RNA-dependent RNA polymerase activity. Anal Biochem 325:247-254. https://doi.org/10.1016/j.ab.2003.10.034.
29. Ferrari E, Wright-Minogue J, Fang JW, Baroudy BM, Lau JY, Hong Z. 1999. Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli. J Virol 73:1649-1654.
30. Ago H, Adachi T, Yoshida A, Yamamoto M, Habuka N, Yatsunami K, Miyano M. 1999. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure 7:1417-1426. https://doi.org/10.1016/S0969-2126(00)80031-3.
31. Ng KK-S, Arnold JJ, Cameron CE. 2008. Structure-function relationships among RNA-dependent RNA polymerases. Curr Top Microbiol Immunol 320:137-156. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18268843/.
32. Arnold JJ, Ghosh SKB, Cameron CE. 1999. Poliovirus RNA-dependent RNA polymerase (3Dpol) divalent cation modulation of primer, template, and nucleotide selection. J Biol Chem 274:37060-37069. https://doi.org/10.1074/jbc.274.52.37060.
33. Yu F, Hasebe F, Inoue S, Mathenge E, Morita K. 2007. Identification and characterization of RNA-dependent RNA polymerase activity in recombinant Japanese encephalitis virus NS5 protein. Arch Virol 152: 1859-1869. https://doi.org/10.1007/s00705-007-1007-0.
34. Siegel RW, Bellon L, Beigelman L, Kao CC. 1999. Use of DNA, RNA, and chimeric templates by a viral RNA-dependent RNA polymerase: evolutionary implications for the transition from the RNA to the DNA world. J Virol 73:6424-6429.
35. Deval J, D'Abramo CM, Zhao Z, McCormick S, Coutsinos D, Hess S, Kvaratskhelia M, Götte M. 2007. High resolution footprinting of the hepatitis C virus polymerase NS5B in complex with RNA. J Biol Chem 282:16907-16916. https://doi.org/10.1074/jbc.M701973200.
36. Morin B, Whelan SP. 2014. Sensitivity of the polymerase of vesicular stomatitis virus to 2′ substitutions in the template and nucleotide triphosphate during initiation and elongation. J Biol Chem 289: 9961-9969. https://doi.org/10.1074/jbc.M113.542761.
37. Sacramento CQ, de Melo GR, Rocha N, Hoelz LVB, Mesquita M, de Freitas CS, Fintelman-Rodrigues N, Marttorelli A, Ferreira AC, Barbosa-Lima G, Bastos MM, de Mello Volotao E, Tschoeke DA, Leomil L, Bozza FA, Bozza PT, Boechat N, Thompson FL, de Filippis AM, Bruning K, Souza T. 2016 July 6. The clinically approved antiviral drug sofosbuvir impairs Brazilian Zika virus replication. bioRxiv https://doi.org/10.1101/061671.
38. Eyer L, Nencka R, Huvarová I, Palus M, Alves MJ, Gould EA, De Clercq E, Růžek D. 2016. Nucleoside inhibitors of Zika virus. J Infect Dis 214: 707-711. https://doi.org/10.1093/infdis/jiw226.
39. Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J. 2013. The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5′-triphosphate towards influenza A virus polymerase. PLoS One 8:e68347. https://doi.org/10.1371/journal.pone.0068347.
40. Fung A, Jin Z, Dyatkina N, Wang G, Beigelman L, Deval J. 2014. Efficiency of incorporation and chain termination determines the inhibition potency of 2′-modified nucleotide analogs against hepatitis C virus polymerase. Antimicrob Agents Chemother 58:3636-3645. https://doi.org/10.1128/AAC.02666-14.
41. Niyomrattanakit P, Abas SN, Lim CC, Beer D, Shi P-Y, Chen Y-L. 2011. A fluorescence-based alkaline phosphatase-coupled polymerase assay for identification of inhibitors of dengue virus RNA-dependent RNA polymerase. J Biomol Screen 16:201-210. https://doi.org/10.1177/1087057110389323.